Herpes simplex - Herpes Sìmplidh
☆ AI Dermatology — Free Service
Ann an toraidhean 2022 Stiftung Warentest às a’ Ghearmailt, cha robh sàsachd luchd-cleachdaidh le ModelDerm ach beagan nas ìsle na le co-chomhairlean telemedicine pàighte.
Ann an toraidhean 2022 Stiftung Warentest às a’ Ghearmailt, cha robh sàsachd luchd-cleachdaidh le ModelDerm ach beagan nas ìsle na le co-chomhairlean telemedicine pàighte.
Herpes simplex air a’ bhile.
Herpes Sìmplidh (Herpes simplex) - Tha galar herpes simplex nas cumanta ann an clann òga na ann an inbhich.
relevance score : -100.0%
ReferencesBidh galar HSV-1 a 'dol air adhart tro ghalar bun-sgoile de cheallan epithelial, a leantainn le latency, gu h-àraidh ann an neurons, agus ath-bheothachadh. Bidh HSV-1 gu tric ag adhbhrachadh sprèadh vesicular tùsail agus ath-chuairteach, gu h-àraidh air beul agus mucosa ginideach. Tha na taisbeanaidhean aige a’ dol bho herpes orolabial gu diofar shuidheachaidhean leithid folliculitis herpetic, galairean craiceann, com-pàirteachadh ocular, agus fìor-chùisean leithid encephalitis herpes. Bidh leigheas anti-bhìorasach a’ cuideachadh le bhith a’ riaghladh galairean HSV.
Herpes simplex virus type 1 (HSV-1) is a member of the Alphaherpesviridae subfamily. Its structure is composed of linear dsDNA, an icosahedral capsid that is 100 to 110 nm in diameter, with a spikey envelope. In general, the pathogenesis of HSV-1 infection follows a cycle of primary infection of epithelial cells, latency primarily in neurons, and reactivation. HSV-1 is responsible for establishing primary and recurrent vesicular eruptions, primarily in the orolabial and genital mucosa. HSV-1 infection has a wide variety of presentations, including orolabial herpes, herpetic sycosis (HSV folliculitis), herpes gladiatorum, herpetic whitlow, ocular HSV infection, herpes encephalitis, Kaposi varicelliform eruption (eczema herpeticum), and severe or chronic HSV infection. Antiviral therapy limits the course of HSV infection.
Herpes simplex virus type 1 (HSV-1) is a member of the Alphaherpesviridae subfamily. Its structure is composed of linear dsDNA, an icosahedral capsid that is 100 to 110 nm in diameter, with a spikey envelope. In general, the pathogenesis of HSV-1 infection follows a cycle of primary infection of epithelial cells, latency primarily in neurons, and reactivation. HSV-1 is responsible for establishing primary and recurrent vesicular eruptions, primarily in the orolabial and genital mucosa. HSV-1 infection has a wide variety of presentations, including orolabial herpes, herpetic sycosis (HSV folliculitis), herpes gladiatorum, herpetic whitlow, ocular HSV infection, herpes encephalitis, Kaposi varicelliform eruption (eczema herpeticum), and severe or chronic HSV infection. Antiviral therapy limits the course of HSV infection.
Tha Herpes simplex virus type 2 (HSV-2) na ghalar farsaing, a’ toirt buaidh air timcheall air 22 % de dh’inbhich aois 12 m bliadhna agus nas sine, gu h-iomlan 45 millean de dhaoine anns na Stàitean Aonaichte. Ged a bhios HSV-1 mar as trice ag adhbhrachadh lotan beòil, faodaidh e cuideachd lotan gnèitheach adhbhrachadh. Ach, nuair a tha leòintean gnèitheach aig euslaintich, mar as trice, is e HSV-2 an prìomh dhroga. Tha comharran briseadh a-mach de HSV-2 gu tric neo‑shoilleir, leithid tachas gnèitheach agus irioslachd, a dh’fhaodadh dàil a chur air breithneachadh agus làimhseachadh. Dh’fhaodadh an dàil seo leantainn gu tuilleadh tar‑chuir aig daoine fa leth gun dìon.
Herpes simplex virus type 2 (HSV-2) continues to be a common infection, affecting approximately 22% of adults ages 12 and older, representing 45 million adults in the United States alone. While HSV-1 often affects the perioral region and can be known to cause genital lesions, HSV-2 is more commonly the consideration when patients present with genital lesions. Despite this, most outbreaks of the infection will present with nonspecific symptoms such as genital itching, irritation, and excoriations, which may cause diagnosis and treatment to be delayed. As a result, further exposure to uninfected individuals may occur.
Herpes simplex virus type 2 (HSV-2) continues to be a common infection, affecting approximately 22% of adults ages 12 and older, representing 45 million adults in the United States alone. While HSV-1 often affects the perioral region and can be known to cause genital lesions, HSV-2 is more commonly the consideration when patients present with genital lesions. Despite this, most outbreaks of the infection will present with nonspecific symptoms such as genital itching, irritation, and excoriations, which may cause diagnosis and treatment to be delayed. As a result, further exposure to uninfected individuals may occur.
Tha an Herpes simplex virus (HSV) gu tric ag adhbhrachadh ghalaran mar herpes genital agus lotan fuar ann an deugairean is inbhich. Nuair a bheir HSV buaidh air pàisde taobh a-staigh na ciad 4‑6 seachdainean de bheatha, faodaidh e tinneas dona adhbhrachadh le buaidh mhòr. Tha e deatamach gun tèid galar HSV ùr‑breith a dhearbhadh gu sgiobalta gus stad a chur air a’ ghalar bho bhith a’ fàs nas motha, a’ cur casg air cùisean eanchainn (eadhon bàs).
Herpes simplex virus (HSV), a member of the Herpesviridae family, is a well-known cause of infections including genital herpes and herpes labialis in the adolescent and adult population. Transmission of HSV infection to an infant during the first 4-6 weeks of life can lead to devastating disease with the potential for poor outcomes. Early diagnosis is imperative when evaluating neonatal HSV infection in order to prevent further disease progression, neurological complications, and even death.
Herpes simplex virus (HSV), a member of the Herpesviridae family, is a well-known cause of infections including genital herpes and herpes labialis in the adolescent and adult population. Transmission of HSV infection to an infant during the first 4-6 weeks of life can lead to devastating disease with the potential for poor outcomes. Early diagnosis is imperative when evaluating neonatal HSV infection in order to prevent further disease progression, neurological complications, and even death.
Tha galar Herpes simplex gu math cumanta agus faodar a chur seachad le bhoireannaich a tha trom le leanabh. Faodaidh am bhìoras seo droch dhuilgheadasan slàinte adhbhrachadh no eadhon bàs ann an ùr-bhreith. Ged a tha e tearc nuair a tha thu trom le leanabh, bidh e tric a’ tachairt aig àm breith. Tha an cunnart nas àirde ma gheibh a’ mhàthair galair anns na h‑ìrean as fhaide den torrachas. Ach, faodar an cunnart seo a lughdachadh le bhith a’ cleachdadh dhrogaichean anti‑bhìorasach no le roghnachadh earrann C ann an suidheachaidhean sònraichte.
Infection with herpes simplex is one of the most common sexually transmitted infections. Because the infection is common in women of reproductive age it can be contracted and transmitted to the fetus during pregnancy and the newborn. Herpes simplex virus is an important cause of neonatal infection, which can lead to death or long-term disabilities. Rarely in the uterus, it occurs frequently during the transmission delivery. The greatest risk of transmission to the fetus and the newborn occurs in case of an initial maternal infection contracted in the second half of pregnancy. The risk of transmission of maternal-fetal-neonatal herpes simplex can be decreased by performing a treatment with antiviral drugs or resorting to a caesarean section in some specific cases.
Infection with herpes simplex is one of the most common sexually transmitted infections. Because the infection is common in women of reproductive age it can be contracted and transmitted to the fetus during pregnancy and the newborn. Herpes simplex virus is an important cause of neonatal infection, which can lead to death or long-term disabilities. Rarely in the uterus, it occurs frequently during the transmission delivery. The greatest risk of transmission to the fetus and the newborn occurs in case of an initial maternal infection contracted in the second half of pregnancy. The risk of transmission of maternal-fetal-neonatal herpes simplex can be decreased by performing a treatment with antiviral drugs or resorting to a caesarean section in some specific cases.
Bidh Herpes simplex virus (HSV) seòrsa 1 agus 2 a’ toirt buaidh air mòran dhaoine air feadh an t-saoghail. Mar as trice, bidh am bhìoras a’ fuireach sàmhach ann an ceallan neo‑innse às dèidh dha a ghlacadh, ach faodaidh e ath‑ghnìomhachadh fad nas fhaide, ag adhbhrachadh lotan fuar. Aig amannan, bidh e a’ leantainn gu fìor dhuilgheadasan leithid galairean sùla, sèid eanchainn, no suidheachaidhean cunnartach ann am pàisdean ùra agus ann an daoine le siostaman dìon lag. Fhad ‘s a tha cungaidhean gnàthach a’ cuideachadh le smachd a chumail air galairean, tha cunnart de dhrogaichean agus fo‑bhuannachdan fhathast na adhbhar dragh. Feumaidh sinn leigheasan ùra gus am bhìoras a làimhseachadh nas èifeachdach.
Infection with herpes simplex virus (HSV) types 1 and 2 is ubiquitous in the human population. Most commonly, virus replication is limited to the epithelia and establishes latency in enervating sensory neurons, reactivating periodically to produce localized recurrent lesions. However, these viruses can also cause severe disease such as recurrent keratitis leading potentially to blindness, as well as encephalitis, and systemic disease in neonates and immunocompromised patients. Although antiviral therapy has allowed continual and substantial improvement in the management of both primary and recurrent infections, resistance to currently available drugs and long-term toxicity pose a current and future threat that should be addressed through the development of new antiviral compounds directed against new targets.
Infection with herpes simplex virus (HSV) types 1 and 2 is ubiquitous in the human population. Most commonly, virus replication is limited to the epithelia and establishes latency in enervating sensory neurons, reactivating periodically to produce localized recurrent lesions. However, these viruses can also cause severe disease such as recurrent keratitis leading potentially to blindness, as well as encephalitis, and systemic disease in neonates and immunocompromised patients. Although antiviral therapy has allowed continual and substantial improvement in the management of both primary and recurrent infections, resistance to currently available drugs and long-term toxicity pose a current and future threat that should be addressed through the development of new antiviral compounds directed against new targets.
Seachain conaltradh corporra sam bith, leithid pògadh leanabh, fhad ’s a tha na blisters an làthair, oir faodaidh conaltradh an ghalar a sgaoileadh gu daoine eile. Bu chòir dhut fois a ghabhail gun a bhith ag òl deoch làidir.
#Acyclovir cream